InnoCore’s SynBiosys® LAI platform enables proven, versatile and highly customizable sustained release formulation solutions, specifically designed for biologic and peptide drug delivery, while preserving structural integrity and biological activity.
Versatile polymer platform enabling the development of bespoke formulations with unique and tunable release kinetics.
Multiple applications: from fragile peptides to more complex proteins and biologics.
Clinically proven: fully biocompatible with no adverse local or systemic effects and an extensive biocompatibility / toxicity data package.
Easy-to-scale manufacturing.
Various dosage forms: microspheres, HME implants, and in-situ forming depots.
Route of administration: systemic and local, including intramuscular, intracardiac, subcutaneous and intra-articular.
Extensive IP protection
With the increase in chronic diseases, drug developers are seeking more targeted, personalised therapeutics. However, these large, complex and sometimes, fragile molecules pose a range of unique challenges around formulation and manufacturing scalability.
SynBiosys®’s biodegradable polymeric drug delivery platform is specifically engineered to overcome these formulation challenges and enhance therapeutic performance. It has multiple applications across a broad range of molecules, from small molecules, peptides and proteins to larger and more complex biologics, including monoclonal antibodies and oligonucleotides.
The InnoCore team, with its 20+ years of formulation development expertise, is behind SynBiosys®, a technology platform which is protected by 16 patent families.
SynBiosys® is not only differentiated in its capabilities but is also commercially and strategically robust. Its unique characteristics translates active pharmaceutical ingredients into novel stable, scalable, and long-acting injectable (LAI) dosage forms with tunable release kinetics.
InnoCore delivers real, measurable value for drug developers and ultimately, for physicians and their patients.
"*" indicates required fields
SynBiosys® is a multi-block copolymer matrix platform, created from well-characterized, regulatory-acceptable building blocks: By varying the composition of the polymeric matrix formulations, unique bespoke release kinetics can be developed.
• Hydrophilic PEG-containing domains – absorb water and swell to offer a protein and peptide-friendly environment, and enable controlled drug diffusion
• Hydrophobic crystalline domains – provide physical crosslinking for integrity, and enabling fine-tuning of swelling and degradation
Once encapsulated within this semicrystalline matrix, biologics and peptides are protected from physiological enzymatic degradation while maintaining their structural integrity and biological activity.
Drug release is governed by precisely controlled diffusion and hydrolysis of the biodegradable polymeric matrix.
SynBiosys® supports a variety of dosage forms and administration routes.
Dosage forms:
Routes of Administration:
Potential therapeutic applications:
InnoCore is actively developing future versions of SynBiosys® to support:
Our aim is to extend SynBiosys®’s data package through InnoCore-formulated LAI reaching commercial status and in time, a SynBiosys® LAI reaching blockbuster status.